Warren Center For Neuroscience Drug Discovery
-
Carrie Jones wins Excellence in Undergraduate Research Mentoring Award at Spring Assembly
This year’s Excellence in Undergraduate Research Mentoring Award was awarded to Carrie Jones, associate professor of pharmacology, for her work understanding schizophrenia, Alzheimer’s disease and addiction and her willingness to support students in her lab. Read MoreApr. 15, 2024
-
Lab-to-Table Conversation: Beyond Addiction: Therapeutic Developments and Societal Impact, on Jan. 24
Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read MoreJan. 11, 2024
-
Innovation Ignition Fund launches a pilot program to support early-stage therapeutic projects with translational viability
The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read MoreJan. 8, 2024
-
Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial
A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark. “Vanderbilt is proud that a discovery by our researchers at the Warren Center… Read MoreDec. 4, 2023
-
Lindsley named 2022 fellow of American Society for Pharmacology and Experimental Therapeutics
Craig W. Lindsley, University Distinguished Professor of Pharmacology, Biochemistry and Chemistry, who holds the William K. Warren, Jr. Chair in Medicine, was recently announced as a 2022 fellow of the American Society for Pharmacology and Experimental Therapeutics for his demonstrated excellence and… Read MoreNov. 30, 2022
-
Vanderbilt, international collaborators discover treatment to slow neurodegenerative diseases
Craig Lindsley, the William K. Warren, Jr. Professor of Medicine and director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, and Jeffrey Conn, founding director of the WCNDD and professor emeritus of pharmacology, have contributed seminal work… Read MoreNov. 15, 2022
-
Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics
Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Down syndrome is a condition in which a person’s having… Read MoreApr. 22, 2022
-
WCNDD-developed Parkinson’s drug to enter next phase of clinical trial
A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug,… Read MoreApr. 4, 2022
-
Hunger signals, including those from cannabinoids, mapped in the brain
Cannabis is well-known for having an effect on eating behaviors. However, how the natural cannabinoid molecules found in the body regulate feeding and eating is not well researched. Masoud Ghamari-Langroudi, research assistant professor of molecular physiology and biophysics, research assistant professor of pharmacology and faculty affiliate… Read MoreMar. 25, 2022
-
Vanderbilt inks collaboration with precision neuroscience company Neumora to continue development of investigational treatment for neuropsychiatric disorders
Vanderbilt University has signed an exclusive, worldwide license and a research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. The licensed program centers around the M4 muscarinic receptor positive allosteric modulator—including… Read MoreFeb. 23, 2022